• The advantages of mucoactive phytopreparations for the treatment of bronchitis in children
en To content Full text of article

The advantages of mucoactive phytopreparations for the treatment of bronchitis in children

Modern Pediatrics.Ukraine.2020.3(107): 54-58. doi 10.15574/SP.2020.107.54
Mishchenko O. Ya.
Institute for Advanced Training of Pharmacy Specialists of the National University of Pharmacy, Kharkiv, Ukraine

For citation: Mishchenko OYa. (2020). The advantages of mucoactive phytopreparations for the treatment of bronchitis in children. Modern Pediatrics. Ukraine. 3(107): 5458. doi 10.15574/SP.2020.107.54
Article received: Jan 14, 2020. Accepted for publication: Apr 18, 2020.

Cough relief and removal of bronchial sputum are the main directions of therapy for bronchitis. Weak force of coughing and unformed ability to expectorate can be the preconditions for poor sputum discharge and, as a result, for the risk of «waterlogging» of the lungs. Therefore, in the treatment of acute bronchitis in children, it is necessary to use mucoactive agents which are able not only to dilute the sputum, but also actively stimulate its excretion from the bronchi, have an anti-inflammatory effect and help reduce the inflammation intensity. Such medications include preparations based on common ivy leaves (Hederisfolia) extract. The results of many trials indicate the effectiveness and safety of ivy extract to reduce the coughing symptom, both independently and in combination with other drugs in the complex treatment of respiratory diseases.
The author claims no conflict of interest.
Key words: children, bronchitis, treatment, herbal remedies, ivy leaf extract.


1. Bolbot YuK. (2015). Mucolytic Therapy for Respiratory Diseases in Children. Zdorov'e rebenka. 1(60): 98—102.

2. Gedery`n Plyushh. Instrukciya do zastosuvannya. info/171272/gederin/

3. Zryachkin N, Makarova O, Guzhinova V et al. (2012). Combination therapy for acute bronchitis in children. Doctor. 8: 74—76.

4. Il'enkova N, Alekseeva O, Chikunov V. (2007). Inflammation markers analysis among children, suffering from acute bronchitis against fenspiride based treatment. Current Pediatrics. 6(6): 49—53.

5. Korovina NA. (2000). Kashel u detey: posobie dlya vrachey. Moskva: Posad: 48.

6. Kruchko TA, Tkachenko OY, Vovk JA. (2014). Treatment of children's cough: from variety of going to inferencing Pedyatryia. Vostochnaia Evropa. 3: 131—140.

7. Marushko YuV, Marushko TV. (2011). Farmakoterapiia zakhvoriuvan orhaniv dykhannia u ditei: Naukovo-informatsiinyi posibnyk. Kyiv: Pryvatna drukarnia FO-P Petryshyn HM: 469.

8. Marushko YuV, Shef HH. (2015). Hostryi bronkhit u ditei. Dytiachyi likar. 8(45): 28—36.

9. Marcian O. (2010) Lechenie ostrogo bronhita u detej i podrostkov. RMZh.18;21: 1269—1273.

10. Mizernickij JuL, Mel'nikova IM. (2013). Mukoliticheskaja i otharkivajushhaja farmakoterapija pri zabolevanijah legkih u detej. Moskva: Medpraktika-M, 120.

11. Namazova-Baranova LS, Kotlyarova MS, Rovenskaya YuV et al. (2014). Comparative Analysis of Effectivenes and Safety of Phyto- and Antibiotic Therapy of Acute Bronchitis in Children: Results of a Multicenter Double Blind Randomized Clinical Trial. Pediatric Pharmacology. 11;5: 22—29.

12. Ostrye respiratornye zabolevaniya u detej: lechenie i profilaktika. (2002). Moskva.

13. Rozinova NN, Sokolova LV, Geppe NA, Sereda EV. (2002). Farmakoterapiya pri bronhitah u detej. Rukovodstvo po farmakoterapii v pediatrii i detskoj hirurgii. Pod red AN Caregorodceva, VA Tabolina. Pulmonologiya. Moskva: 145—154.

14. Samsygina GA. (2008). Acute bronchitis in children and its treatment. Consilium Medicum. Pediatrics. 2: 4—8.

15. Selimzyanova LR, Promyslova EA, Vishneva EA. (2013). Cough phytotherapy in children. Pediatric pharmacology. 10;4: 128—130. https://doi.org/10.15690/pf.v10i4.766

16. Soroka ND, Korshunova EV, Rjabyh OV, Balackaja GM i dr. (2010). Jeffektivnost' i bezopasnost' ingaljacionnogo metoda lechenija suhim jekstraktom list'ev pljushha ostryh respiratornyh zabolevanij u detej rannego vozrasta. Lechashhij vrach. 6: 14—17.

17. Tumanov VA, Pokanevich VV, Garnik TP, Frolov VM, Peresadin NA. (2012). Phytotherapy: application modern lines in medical practice and perspectives of the further development. Phitoterapiya. 1: 4—11.

18. Chernikov VV. (2012). Application of vegetable drugs for treating cough in children. Pediatric pharmacology. 9;6: 105—109. https://doi.org/10.15690/pf.v9i6.527

19. Ernst E. (2007). Herbal medicines: balancing benefits and risks. Novartis Found Symp. 282: 154—67; discussion 167—72, 212—8. https://doi.org/10.1002/9780470319444.ch11; PMid:17913230

20. Fazio S, Pouso J, Dolinsky D, Fernandez A et al. (2009). Tolerance, safety and efficacy of Hedera helix extract in inflammatory bronchial diseases under clinical practice conditions: a prospective, open, multicentre postmarketing study in 9657 patients. Phytomedicine.16(1): 17—24. https://doi.org/10.1016/j.phymed.2006.05.003; PMid:16860549

21. Felix Holzinger, Jean0Francois Chenot. (2011). Systematic Review of Clinical Trials assessing the effectiveness of Ivy Leaf (Hedera Helix) for acute upper respiratory tract infections. Evidence-Based Complementary and Alternative Medicine. 2011. Article ID 382789. 9 p. https://doi.org/10.1155/2011/382789; PMid:20976077 PMCid:PMC2957147

22. Greunke C, Hage-Hulsmann A, Sorkalla T, Keksel N et al. (2015). A systematic study on the influence of the main ingredients of an ivy leaves dry extract on the b2-adrenergic responsiveness of human airway smooth muscle cells. Pulm Pharmacol Ther.31: 92—98. https://doi.org/10.1016/j.pupt.2014.09.002; PMid:25234924

23. Hocaoglu AB, Karaman O, Erge DO et al. (2012). Effect of Hedera helix on lung histopathology in chronic asthma. Iran J Allergy Asthma Immunol. 11: 316—323.

24. Janka Schulte-Michels, Anne Wolf, Stefan Aatz et al. (2016). α-Hederin inhibits G-protein-coupled receptor kinase2-mediated phosphorylation of β2-adrenergic receptors. Phytomedicine.23: 52—57. https://doi.org/10.1016/j.phymed.2015.12.001; PMid:26902407

25. Janka Schulte-Michels, Christina Keksel, Hanns Haberlein, Sebastian Franken. (2018). Anti-inflammatory effects of ivy leaves dry extract: influence on transcriptional activity of NFκB. Inflammopharmacology. 27(2). https://doi.org/10.1007/s10787-018-0494-9; PMid:29748881 PMCid:PMC6482290

26. Marquardt P, Kaft K, Nieber K. (2015). Clinical trials with herbal medicinal products in children: a literature analysis. Wien Med Wochenschr.165 (11–12): 236—242. https://doi.org/10.1007/s10354-015-0373-6; PMid:26183729

27. Schmidt M, Thomsen M, Schmidt U. (2012). Suitability of ivy extract for the treatment of paediatric cough. Phytother Res.26(12): 1942—1947. https://doi.org/10.1002/ptr.4671; PMid:22532491

28. Sieben A, Prenner L, Sorkalla T, Wolf A et al. (2009). α-Hederin, but not hederacoside C and hederagenin from Hedera helix, affects the binding behaviour, dynamics and regulation of beta 2-adrenergic receptors. Biochemistry. 48: 3477—3482. https://doi.org/10.1021/bi802036b; PMid:19278262

29. Suleyman H, Mshvildadze V, Gepdiremen A, Elias R. (2003). Acute and chronic antiinflammatory profile of the ivy plant, Hedera helix, in rats. Phytomedicine 10: 370—374. https://doi.org/10.1078/0944-7113-00260; PMid:12834000

30. World Health Organization. (2010). WHO monographs on medicinal plants commonly used in the Newly Independent States (NIS). Geneva: WHO-Press, 464.